Contact Us
Company Overview
|
Pipeline / Clinical Trials
|
Science & Discovery
|
Business Development
|
Investors
Overview
|
Stock Data
|
Governance
|
SEC Filings
|
News & Events
|
Presentations
|
Fundamentals
|
Information Request
Press Release Archive
Press Release Archive
2010
>
2009
>
2008
>
2007
> 2006 >
2005
>
2004
>
2003
>
2002
>
2001
December 27, 2006
Wall Street Reporter Interviews RegeneRx CEO
December 22, 2006
RegeneRx Closes $9.55 Million Offering of Common Stock
December 18, 2006
RegeneRx Raises $9.55 Million in Private Placement
November 17, 2006
TB4 is Essential for Coronary Vessel Development Report U.K. and U.S. Scientists
November 8, 2006
Dr. Hynda Kleinman Joins RegeneRx Medical and Scientific Advisory Board
October 12, 2006
RegeneRx Receives Australian TB4 Patent for Treatment of Epidermolysis Bullosa
September 11, 2006
New Study Confirms TB4 Improves Cardiovascular Function after Heart Attack; Collaboration with Pharmaceutical Firm Reproduces and Extends Findings Originally Published in Nature
August 9, 2006
RegeneRx Receives $545,000 Grant from FDA; Funding for Clinical Development of TB4 for Epidermolysis Bullosa
August 1, 2006
NIH Researchers Find RegeneRx's Drug Candidate Regulates Key Proteins Important in Wound Repair; Research Team Offers New Insights Into TB4's Mechanism of Action
July 26, 2006
RegeneRx Holds 2006 Annual Stockholders' Meeting
July 3, 2006
RegeneRx's Wound Healing Technology Patent to be Granted in Mexico; Technology Licensed from NIH in 1999
June 27, 2006
RegeneRx CEO Featured in BioExecutive International Cover Story
June 12, 2006
RegeneRx to Present at 17th Annual Wall Street Analyst Forum
April 25, 2006
Researchers Find RegeneRx's TB4 Prevents Cell Death Caused by Common Eye Drop Preservative; TB4 Prevents BAK-mediated Apoptosis in Human Corneal and Conjunctival Epithelial Cells
April 6, 2006
RegeneRx Updates Web Site
April 3, 2006
CORRECTING and REPLACING RegeneRx to Present at Biotechnology Industry Organization's 2006 Business Forum
April 3, 2006
RegeneRx to Present at Biotechnology Industry Organization's 2006 Business Forum
March 31, 2006
RegeneRx Reports 2005 Year-End Results
March 21, 2006
RegeneRx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year End Earnings Release and Conference Call
March 16, 2006
RegeneRx Closes $7.3 Million Offering of Common Stock
March 7, 2006
RegeneRx Announces $7.3 Million Offering of Common Stock
March 2, 2006
RegeneRx's Chief Executive Interviewed by Wall Street Transcript For Annual Biotechnology Issue
March 1, 2006
Researchers Find New Evidence of RegeneRx's TB4 Wound Healing Activities in the Eye; Data to be Reported at 2006 ARVO Meeting
February 15, 2006
RegeneRx Adds L. Thompson Bowles, M.D., Ph.D. To Board of Directors
home
|
Contact Us
|
Resources
|
Site Map
|
Search
